Literature DB >> 825775

Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase.

A Cohen, D Doyle, D W Martin, A J Ammann.   

Abstract

To delineate the normal function of purine nucleoside phosphorylase and to understand the pathogenesis of the immune dysfunction associated with deficiency of this enzyme, we studied purine metabolism in a patient deficient in purine nucleoside phosphorylase, her erythrocytes and cultured fibroblasts. She exhibited severe hypouricemia and hypouricosuria but excreted excessive amounts of purines in her urine, the major components of which were inosine and guanosine. Her urine also contained deoxyinosine, deoxyguanosine and uric acid 9-N riboside. The patient's erythrocytes but not her cultured fibroblasts contained increased concentrations of phosphoribosylpyrophosphate and inosine. The metabolic abnormalities resembled those in the erythrocytes of patients with the Lesch-Nyhan syndrome. Purine nucleoside phosphorylase is a necessary component of the major, if not the sole, pathway for the conversion of purine nucleosides and nucleotides to uric acid. The increased intracellular concentrations of inosine may, by inhibiting adenosine deaminase, be related to the immunologic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 825775     DOI: 10.1056/NEJM197612232952603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  43 in total

1.  Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.

Authors:  B Ullman; L J Gudas; S M Clift; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

2.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

3.  A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Authors:  Leah C Jimmerson; Lane R Bushman; Michelle L Ray; Peter L Anderson; Jennifer J Kiser
Journal:  Pharm Res       Date:  2016-09-15       Impact factor: 4.200

Review 4.  Heberden oration 1979: human aberrations of purine metabolism and their significance for rheumatology.

Authors:  J E Seegmiller
Journal:  Ann Rheum Dis       Date:  1980-04       Impact factor: 19.103

5.  Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function.

Authors:  E W Gelfand; J J Lee; H M Dosch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

6.  Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.

Authors:  B S Mitchell; E Mejias; P E Daddona; W N Kelley
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

7.  Effect of NADH on hypoxanthine hydroxylation by native NAD+-dependent xanthine oxidoreductase of rat liver, and the possible biological role of this effect.

Authors:  Z W Kamiński; M M Jezewska
Journal:  Biochem J       Date:  1981-12-15       Impact factor: 3.857

8.  Purine oversecretion in cultured murine lymphoma cells deficient in adenylosuccinate synthetase: genetic model for inherited hyperuricemia and gout.

Authors:  B Ullman; M A Wormsted; M B Cohen; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

Review 9.  Transition States, analogues, and drug development.

Authors:  Vern L Schramm
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

10.  Immune deficiency due to adenosine deaminase and purine nucleoside phosphorylase deficiency: a simple diagnostic test.

Authors:  J L Maddocks; S A Al-Safi; G Wilson
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.